Image

Global Morvan Syndrome Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Feb 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Feb 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Morvan Syndrome Market, By Diagnosis (Cerebrospinal Fluid (CSF) Analysis, Brain MRI, Electroencephalogram, Positron Emission Tomography, Electromyography, Antibodies Detection), Treatment (Gold Therapy, Antiepileptic Agents, Procedures), End-User (Research Institutes, Hospitals, Others), Distribution Channel (Hospital Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Morvan Syndrome Market Market Analysis and Insights: Global Morvan Syndrome Market

The morvan syndrome market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 5.60% in the above-mentioned research forecast period. Ongoing research and studies related to the novel treatment may increase the morvan syndrome market growth.  

For instance,

  • The study was published in the journal “Asian Journal of Transfusion Science” that a novel treatment was used for morvan syndrome that is therapeutic plasma exchange (TPE). This treatment was used on the patient when the drug therapy was not effective and after the fifth TPE, the patient was able to perform the activities such as walking with support, autonomic dysfunction and behavioural abnormalities was also decreased.

Morvan syndrome is characterized by the rare and life-threatening neurological disorder. This disease is also categorized by the dysautonomia, neuromyotonia and encephalopathy along with severe insomnia. Some of the reports have confirmed that the disease shows some signs of central, peripheral and autonomic hyperactivity along with systemic manifestations such as weight loss or fever. The cause for the disease can be poisoning from the heavy metals such as manganese or mercury. The disease mainly affects the male population. The prognosis of the disease is very poor when related to with thymoma.

Increasing awareness about healthcare and investments in R&D in pharmaceutical and life sciences sectors are the factors for the morvan syndrome market growth. In addition, growing awareness about autoimmune diseases among consumers may increase the morvan syndrome market growth. Morvan syndrome is rare disease and only few patients were reported according to the literature and dearth of understanding regarding the basic etiology of the disease are some of the factors which may hamper the morvan syndrome market growth.  

This morvan syndrome market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the morvan syndrome market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Morvan Syndrome Market Scope and Market Size

The morvan syndrome market is segmented on the basis of diagnosis, treatment, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of diagnosis, the morvan syndrome market is segmented into cerebrospinal fluid (CSF) analysis, brain MRI, electroencephalogram, positron emission tomography, electromyography and antibodies detection. Antibodies detection is further segmented to VGKC-complex antibodies.
  • On the basis of treatment, the morvan syndrome market is segmented into gold therapy, antiepileptic agents and procedures. Antiepileptic agents are further segmented to carbamazepine, valproate, phenobarbital and phenytoin. Procedures are further segmented to thymectomy.
  • On the basis of end-user, the morvan syndrome market is segmented to research institutes, hospitals and others.
  • On the basis of distribution channel, the morvan syndrome market is segmented into hospital pharmacy and others.

Global Morvan Syndrome Market Country Level Analysis

Global morvan syndrome market is analysed and market size information is provided by country, diagnosis, treatment, end-user and distribution channel as referenced above.

The countries covered in the morvan syndrome market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share because of increase in healthcare expenditure. In 2019, the healthcare expenditure has increased 4.6% that is USD 3.80 trillion or USD 11,582 per person. Europe holds the second position in the market share due to rising incidence of chronic diseases such as autoimmune disease and government support for the research and development.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The morvan syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to morvan syndrome market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the morvan syndrome market in the growth period.

Competitive Landscape and Global Morvan Syndrome Market Share Analysis

The morvan syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to morvan syndrome market.

The major players covered in the global morvan syndrome market report are Pfizer Inc, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd, Allergan, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Endo International plc, Sun Pharmaceutical Industries Ltd, Mylan N.V., Lupin, Cipla Inc, Aurobindo Pharma, Torrent Pharmaceuticals Ltd, Sanofi, Merck & Co., Inc, Apotex Inc, Mayne Pharma Group Limited among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-

Why Choose Us


Frequently Asked Questions